Journal
CHEMICAL BIOLOGY & DRUG DESIGN
Volume 90, Issue 4, Pages 609-617Publisher
WILEY
DOI: 10.1111/cbdd.12984
Keywords
anticancer agent; antiproliferative activity; diarylurea derivative; molecular docking; rational drug design
Funding
- Zhufeng Scholar Program
- 5150 Scientific Plan
- youth special fund for PhD of Qingdao [16-5-1-61-jch]
Ask authors/readers for more resources
A series of novel indazole-based diarylurea derivatives targeting c-kit were designed by structure-based drug design. The derivatives were prepared, and their antiproliferative activities were evaluated against human colon cancer HCT-116 cell line and hepatocellular carcinoma PLC/PRF/5 cell line. The antiproliferative activities demonstrated that six of nine compounds exhibited comparable activities with sorafenib against HCT-116. The structure-activity relationship (SAR) analysis indicated that the indazole ring part tolerated different kinds of substituents, and the N position of the central pyridine ring played key roles in antiproliferative activity. The SAR and interaction mechanisms were further explored using molecular docking method. Compound 1i with N-(2-(pyrrolidin-1-yl)ethyl)-carboxamide possessed improved solubility, 596.1ng/ml and best activities, IC50 at 1.0m against HCT-116, and 3.48m against PLC/PRF/5. It is a promising anticancer agent for further development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available